KR20180030913A - 아릴 치환된 비시클릭 헤테로아릴 화합물 - Google Patents

아릴 치환된 비시클릭 헤테로아릴 화합물 Download PDF

Info

Publication number
KR20180030913A
KR20180030913A KR1020187005405A KR20187005405A KR20180030913A KR 20180030913 A KR20180030913 A KR 20180030913A KR 1020187005405 A KR1020187005405 A KR 1020187005405A KR 20187005405 A KR20187005405 A KR 20187005405A KR 20180030913 A KR20180030913 A KR 20180030913A
Authority
KR
South Korea
Prior art keywords
alkyl
alkoxy
aryl
fluoroalkyl
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187005405A
Other languages
English (en)
Korean (ko)
Inventor
샤오준 장
샤오판 젱
루이스 에스. 추팍
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20180030913A publication Critical patent/KR20180030913A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187005405A 2015-07-30 2016-07-28 아릴 치환된 비시클릭 헤테로아릴 화합물 Withdrawn KR20180030913A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562198706P 2015-07-30 2015-07-30
US62/198,706 2015-07-30
PCT/US2016/044388 WO2017019828A1 (en) 2015-07-30 2016-07-28 Aryl substituted bicyclic heteroaryl compounds

Publications (1)

Publication Number Publication Date
KR20180030913A true KR20180030913A (ko) 2018-03-26

Family

ID=56609996

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187005405A Withdrawn KR20180030913A (ko) 2015-07-30 2016-07-28 아릴 치환된 비시클릭 헤테로아릴 화합물

Country Status (6)

Country Link
US (1) US10517870B2 (enExample)
EP (1) EP3328839A1 (enExample)
JP (1) JP2018525371A (enExample)
KR (1) KR20180030913A (enExample)
CN (1) CN108137514A (enExample)
WO (1) WO2017019828A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3484874B1 (en) 2016-07-14 2020-04-29 Bristol-Myers Squibb Company Monocyclic heteroaryl substituted compounds
EP3484881B1 (en) 2016-07-14 2020-04-29 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
US20190315774A1 (en) * 2016-07-14 2019-10-17 Bristol-Myers Squibb Company Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as par4 inhibitors
JP7058256B2 (ja) 2016-07-14 2022-04-21 ブリストル－マイヤーズ スクイブ カンパニー 二環式ヘテロアリール置換化合物
WO2019113312A1 (en) * 2017-12-08 2019-06-13 Innocrin Pharmaceuticals, Inc. Anticancer compound process
CN111440161B (zh) * 2020-05-15 2023-04-14 中国药科大学 一种具有par4拮抗活性的二环杂芳基类化合物及其应用
CN111440146B (zh) * 2020-05-15 2022-10-21 中国药科大学 一种具有par4拮抗活性的苯并三嗪类化合物及其应用
CN116041341B (zh) * 2022-11-24 2025-02-28 中国药科大学 一种喹唑啉类par4拮抗剂及其医药应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1164459A (en) 1980-11-11 1984-03-27 Yung-Hsiung Yang Process for preparing (imidazo¬1,2-a|pyridine- 2-yl)-carbostyril or -3,4-dihydrocarbostyryl derivatives
US5110347A (en) 1990-11-26 1992-05-05 E. I Du Pont De Nemours And Company Substituted fused heterocyclic herbicides
TW279162B (enExample) 1991-09-26 1996-06-21 Mitsubishi Chem Corp
ATE246184T1 (de) 1996-11-06 2003-08-15 Darwin Discovery Ltd Chinoline und deren therapeutische verwendung
KR20010042298A (ko) * 1998-03-31 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 인자 Ｘａ 및 트롬빈과 같은 세린 프로테아제억제제로서의 퀴녹살리논
US7511145B2 (en) * 2003-08-01 2009-03-31 Genelabs Technologies, Inc. Bicyclic heteroaryl derivatives
US7501416B2 (en) * 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
EP2168968B1 (en) * 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
AU2006204917A1 (en) * 2005-01-14 2006-07-20 Smithkline Beecham Corporation Indole derivatives for treating viral infections
JP2009023986A (ja) * 2006-11-08 2009-02-05 Pharma Ip 抗癌剤としてのビアリール誘導体
KR101472607B1 (ko) * 2007-02-20 2014-12-15 노파르티스 아게 지질 키나제 및 ｍＴＯＲ의 이중 억제제로서의 이미다조퀴놀린
EP2150255A4 (en) * 2007-05-10 2011-10-05 Glaxosmithkline Llc CHINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
AR066879A1 (es) * 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
EP2173354A4 (en) * 2007-08-09 2011-10-05 Glaxosmithkline Llc CHINOXALIN DERIVATIVES AS PI3 KINASE INHIBITORS
JP5734654B2 (ja) * 2007-09-17 2015-06-17 アッヴィ・バハマズ・リミテッド Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体
EP2282995B1 (en) * 2008-05-23 2015-08-26 Novartis AG Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
WO2010052448A2 (en) * 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
BRPI0922366B8 (pt) * 2008-12-03 2021-05-25 Presidio Pharmaceuticals Inc composto, composição farmacêutica e uso de um composto
EP2241557A1 (de) * 2009-04-02 2010-10-20 Æterna Zentaris GmbH Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen
AR077004A1 (es) * 2009-06-09 2011-07-27 Hoffmann La Roche Compuestos heterociclicos antivirales
WO2011026579A1 (en) 2009-09-04 2011-03-10 Bayer Schering Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
US20110274648A1 (en) * 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011060526A1 (en) 2009-11-18 2011-05-26 National Research Council Of Canada Fluorinated monomers, oligomers and polymers for use in organic electronic devices
CN102753545A (zh) * 2009-12-15 2012-10-24 盐野义制药株式会社 具有血管内皮脂酶抑制活性的噁二唑衍生物
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
US8993758B2 (en) * 2010-11-22 2015-03-31 Board Of Regents Of The University Of Nebraska Substituted quinoxalines and uses thereof
KR101992311B1 (ko) * 2011-05-04 2019-09-27 리젠 파마슈티컬스 소시에떼 아노님 단백질 키나아제의 조절제로서 신규한 화합물
CN102532932B (zh) 2012-01-12 2014-01-08 复旦大学 一类含有吡嗪环的有机染料及其制备方法和应用
EP2872161B1 (en) * 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
JP2016509576A (ja) * 2012-12-20 2016-03-31 バイエル ファーマ アクチエンゲゼルシャフト Ｂｅｔタンパク質阻害性ジヒドロキノキザリノン類
CN105492439B (zh) * 2013-06-21 2019-11-22 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的取代的双环化合物

Also Published As

Publication number Publication date
JP2018525371A (ja) 2018-09-06
US20180214445A1 (en) 2018-08-02
US10517870B2 (en) 2019-12-31
EP3328839A1 (en) 2018-06-06
WO2017019828A1 (en) 2017-02-02
CN108137514A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
KR20180030913A (ko) 아릴 치환된 비시클릭 헤테로아릴 화합물
JP6790183B2 (ja) Ａｓｋ１阻害剤の固体形態
CN105636953B (zh) 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途
CN111909108B (zh) 联苯类化合物及其制备方法和医药用途
CN112424185B (zh) 含苯环的化合物、其制备方法及应用
CN112661745A (zh) 用作cdk7激酶抑制剂的化合物及其应用
KR102492715B1 (ko) 모노시클릭 헤테로아릴 치환된 화합물
CN107835813A (zh) 用于治疗和预防乙型肝炎病毒感染的新的6,7‑二氢吡啶并[2,1‑a]酞嗪‑2‑酮类化合物
CN106573906A (zh) 哌啶‑二酮衍生物
CN107250137B (zh) 作为长效dpp-iv抑制剂的取代的氨基六元饱和杂脂环类
WO2020020288A1 (zh) 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途
WO2018024188A1 (zh) 多环化合物、其制备方法、药物组合物及应用
CN115960105A (zh) Kras g12d抑制剂及其在医药上的应用
KR20240004634A (ko) 삼환식 유비퀴틴 특이적 프로테아제 1 억제제 및 이의 용도
CN109311865A (zh) 抗乙肝病毒的吡唑-噁唑烷酮类化合物
CN105051008A (zh) 胍基苯甲酸酯化合物
CN116693447B (zh) 酮酰胺类衍生物及其制药用途
CA3174266A1 (en) Grk2 inhibitors and uses thereof
WO2006077851A1 (ja) キノロン誘導体又はその塩
CN116969918A (zh) 氟取代的吡啶酮类衍生物及其药物组合物、制备方法和用途
AU2019382521B2 (en) Crystal form of hepatitis B surface antigen inhibitor
JP2023506321A (ja) 心臓病の治療のための心筋細胞増殖活性を有する複素環式誘導体の使用
WO2022122035A1 (zh) 凝血因子XIa抑制剂及其制备方法和应用
CN119306762A (zh) 基于不稳定的氨基酸的新型癌症protac药物化合物的设计与应用
JP2024525152A (ja) ＧＲＫ５調節剤としての３－置換１Ｈ－ピロロ［２，３－ｂ］ピリジン

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180223

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination